Skip to content
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Culture
    • Careers
    • Partnering
    • Contact Form
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Culture
    • Careers
    • Partnering
    • Contact Form

Category: Publications

ACC 2023 Poster: Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation

← Previous

© 2024 Mineralys Therapeutics, Inc.

Terms & Conditions
Privacy Policy
X-twitter
Terms & Conditions
Privacy Policy

© 2024 Mineralys Therapeutics, Inc.

X-twitter